PCSK9 and metabolic dysfunction-associated steatotic liver disease: Using in vitro and in vivo models of PCSK9 inhibition, Demers et al. reported increased hepatic triglyceride content, suggesting that elevated CD36 levels in the liver may lead to increased susceptibility to NAFLD [76].